Delivery Order SPE2DB24D2003-SPE2DB25FXKU0
- Not listed
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract worth $1,943.76 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp, with a potential value of up to $999,999,999.00 and a performance period through December 31, 2025. The...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of the AmerisourceBergen Corporation. The $3,562.80 contract is for the provision of Lantus SoloStar 100 Unit/mL 3mL insulin pens. This delivery order is placed under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with DLA, which has a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. The contract has a potential value of $1,911.67 and a completion date of March 5, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of up to $999,999,999.00 and a...
- The Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distributor Amerisourcebergen Corporation. The $1,002.40 contract is for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. This delivery order is part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 with Amerisourcebergen Drug Corp as the sole prime...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply Lantus SoloStar 100 Unit/mL 3mL insulin pens. The $1,295.20 contract has a completion date of January 31, 2024 and does not have a set-aside designation. Amerisourcebergen Drug Corp, as the prime contractor, will deliver these pharmaceutical products to support military treatment programs and facilities. This order is...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of Lantus SoloStar 100 unit/mL 3mL insulin pens. The $2,375.20 contract has an ultimate completion date of April 1, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with DLA valued at up to $999,999,999.00, which serves as the primary...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. The $1,187.60 firm fixed price order has a period of performance through November 30, 2022. AmerisourceBergen is the prime contractor, and there is no indication of any set-aside designation for this award. The order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. The contract has a completion date of February 27, 2024 and a potential value of $4,202.62. The contract does not have a set-aside designation. Amerisourcebergen Drug Corp serves as the prime contractor for this delivery order, which is...
- The Defense Logistics Agency awarded a $13,235 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of Lantus SoloStar 100 unit/ml pre-filled insulin pens. The delivery order was issued under an indefinite-delivery/indefinite-quantity contract vehicle and calls for the delivery of this medical product to a facility in Conshohocken, Pennsylvania by July 12, 2023. As a leading provider of pharmaceuticals and medical supplies to the Department of Defense,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lantus SoloStar 100 unit/mL 3mL insulin pens. The $2,106.08 firm-fixed-price contract has an ultimate completion date of April 17, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXKU0Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,278.50 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. This firm fixed-price, non-set-aside delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a routine transaction under AmerisourceBergen's larger contract vehicle with DLA, through which the company supplies critical pharmaceutical products and medical supplies to support military and federal healthcare systems. This award is part of AmerisourceBergen's significant Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen supplies a comprehensive range of medications, vaccines, and medical devices across multiple therapeutic domains to support defense and veteran healthcare operations globally. The company's contract portfolio demonstrates its established capability to meet federal procurement requirements through competitive awards, positioning it as a primary vendor for military pharmaceutical supply needs across diverse product categories and order volumes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 7/18/25 |